The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Global

Pivotal Therapeutics Files Five International Patent Applications

23-Feb-2012 | Source : | Visits : 8461
WOODBRIDGE, Ontario - Pivotal Therapeutics Inc. announced in a press release that it has filed five international patent applications under the Patent Cooperation Treaty (PCT), directed toward its novel lead product VASCAZENTM, and combinations thereof with certain cardiovascular treatment agents.

The PCT is an international patent application. A PCT application has the effect of a national application for a patent in any of the 142 designated PCT countries, and thereby secures patent pending status for VASCAZENTM in all the designated countries. This filing follows from the Provisional Patent filings of last year, adding significant data demonstrating the unique properties of VASCAZENTM.

"The filing of these PCT patent applications is a critical step in Pivotal’s strategy for securing global Intellectual Property rights for VASCAZENTM" says Rachelle MacSweeney, President of Pivotal Therapeutics. "These filings represent the culmination of research conducted over the last several years which quantify the unique properties of our product's ultra high purity prescription-grade Omega-3 formulation in meeting the dietary Omega-3 deficient needs of patients with cardiovascular disease, by elevating Eicosapentaenoic (EPA) and Docosahexaenoic (DHA) to levels associated with a reduced risk of cardiovascular complications”.

By ensuring that VASCAZEN'sTM unique EPA to DHA ratio fish oils are of the highest purity, Pivotal Therapeutics is able to maximize the correction of the dietary deficiency provided by VASCAZENTM either alone or in combination with other active ingredients in cardiovascular patients.

"Pivotal’s latest patent filings create value while demonstrating its dedication to producing novel prescription medical food products that further the goal of continuing to develop cutting edge medical foods for the dietary management of patients with a variety of metabolic deficiencies,” says Dr. George Jackowski, Chief Scientific Officer & Chair of Pivotal Therapeutics.

With offices in Toronto, Canada and Boca Raton, Florida, Pivotal Therapeutics is a publicly traded specialty pharmaceutical company with a focus on the treatment of cardiovascular disease and overall health.

Related Articles